The overall objectiv is to obtain preliminary evidence of efficacy of novel agents for the
management of relapsed ovarian cancer, and in part 2 efficacy of novel agents compared to the
standard of care (SoC).
Phase:
Phase 2
Details
Lead Sponsor:
Nordic Society for Gynaecologic Oncology Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Collaborators:
ANZGOG: The Australia New Zealand Gynaecological Oncology Group Australia New Zealand Gynaecological Oncology Group Belgian Gynaecological Oncology Group BGOG: Belgian Gynaelogical Onology Group, Belgium COGI: Cooperative Ovarian Cancer Group for Immunotherapy ENGOT: European Network of Gynecological Oncological Trial Groups, EU European Network of Gynaecological Oncological Trial Groups (ENGOT) GCIG: Gynecologic Cancer InterGroup GOTIC: Gynecologic Oncology Trial and Investigation Consortium, Japan Gynecologic Cancer Intergroup (GCIG) Gynecologic Oncology Trial & Investigation Consortium KGOG: Korean Gynaelogical Onology Group, Korea NOGGO: Nord-Ostdeutsche Gesellschaft Fur Gynäkologische Onkologie, Germany PMHC: The Princess Margaret Hospital Consortium, Canada Princess Margaret Hospital, Canada SGCTG: The Scottish Gynaecological Cancer Trials Group, UK